Published in J Am Soc Hypertens on January 16, 2013
Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24
Effect of olmesartan on blood pressure in patients with hypertension: specification on causality. J Hum Hypertens (2014) 0.83
Formulations of Amlodipine: A Review. J Pharm (Cairo) (2016) 0.75
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol (2005) 3.21
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res (2010) 2.09
Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther (2014) 2.07
Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res (2007) 1.61
Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens (2007) 1.56
Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther (2004) 1.55
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res (2010) 1.54
Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. Cancer Biol Ther (2006) 1.43
Irbesartan and hydrochlorothiazide association in the treatment of hypertension. Curr Vasc Pharmacol (2009) 1.40
Additional acetylcholine (ACh) binding site at alpha4/alpha4 interface of (alpha4beta2)2alpha4 nicotinic receptor influences agonist sensitivity. J Biol Chem (2011) 1.39
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother (2005) 1.30
Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol (2005) 1.30
Prospects for the development of novel anti-hyperlipidemic drugs. Curr Opin Investig Drugs (2006) 1.27
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium (2006) 1.27
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens (2005) 1.26
Quantifying signals with power-law correlations: a comparative study of detrended fluctuation analysis and detrended moving average techniques. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 1.26
Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int (2009) 1.21
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther (2012) 1.18
Prevalence of CKD in northeastern Italy: results of the INCIPE study and comparison with NHANES. Clin J Am Soc Nephrol (2010) 1.15
Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther (2012) 1.12
KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int J Oncol (2006) 1.11
α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci (2012) 1.09
Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf (2012) 1.08
Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem (2011) 1.07
TGFbeta1 induces epithelial-mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture. Int J Exp Pathol (2006) 1.06
Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis (2004) 1.05
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels (2007) 1.05
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism (2009) 1.04
Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Farmaco (2003) 1.03
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis (2005) 1.01
Synthesis and antitumor properties of 2,5-bis(3'-indolyl)thiophenes: analogues of marine alkaloid nortopsentin. Bioorg Med Chem Lett (2007) 0.99
Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus. Hum Pathol (2008) 0.98
Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. J Bone Miner Res (2012) 0.97
Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies. Curr Vasc Pharmacol (2011) 0.96
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol (2012) 0.96
Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project. Aging Ment Health (2010) 0.96
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res (2007) 0.95
Synthesis and antitumor activity of 2,5-bis(3'-indolyl)-furans and 3,5-bis(3'-indolyl)-isoxazoles, nortopsentin analogues. Bioorg Med Chem (2010) 0.95
Apolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer's disease. Neurosci Lett (2004) 0.95
GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol (2012) 0.95
3,5-bis(3'-indolyl)pyrazoles, analogues of marine alkaloid nortopsentin: synthesis and antitumor properties. Bioorg Med Chem Lett (2007) 0.94
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. Diabetes Technol Ther (2009) 0.93
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol (2011) 0.93
Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res (2013) 0.93
Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens (2010) 0.93
Synthesis and antitumor activity of 3-(2-phenyl-1,3-thiazol-4-yl)-1H-indoles and 3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles. ChemMedChem (2011) 0.93
Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation (2013) 0.93
The origin of nephrocalcinosis, Randall's plaque and renal stones: a cell biology viewpoint. Arch Ital Urol Androl (2009) 0.92
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract (2012) 0.92
Hypertension: management perspectives. Expert Opin Pharmacother (2012) 0.91
Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther (2012) 0.90
Crystals, Randall's plaques and renal stones: do bone and atherosclerosis teach us something? J Nephrol (2004) 0.90
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc (2006) 0.90
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag (2007) 0.90
The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther (2003) 0.90
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol (2012) 0.89
Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr (2004) 0.89
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract (2004) 0.89
Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. Arch Med Sci (2013) 0.89
Perforin, Granzyme B, and fas ligand for molecular diagnosis of acute renal-allograft rejection: analyses on serial biopsies suggest methodological issues. Transplantation (2006) 0.89
An unusual association of contralateral congenital small kidney, reduced renal function and hyperparathyroidism in sponge kidney patients: on the track of the molecular basis. Nephrol Dial Transplant (2005) 0.88
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart Vessels (2009) 0.88
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med (2009) 0.88